Cholera Vaccines Market Size, Share & Trends Report | 2031

Report Description

Cholera Vaccines Market Outlook 2031

The global cholera vaccines market size was USD 4.90 Billion in 2022 and is projected to reach USD 12.64 Billion by 2031 expand at a substantial CAGR 11.1% during the forecast period, 2023–2031. The growth of the market is attributed to the wide incidence of cholera and growing need for disease prevention vaccines.

Cholera is a type of disease caused by the intake of infected food and water that normally present the bacteria called, Vibrio Cholerae. The infection has a brief incubation time, ranging from a few hours to five days, and is characterized by watery diarrhea in abundance. Cholera is a disease that can be lethal in some cases. The disease manifests itself in both endemic and epidemic forms, and is linked to inadequate hygiene, sanitization, and a lack of safe drinking water.

Get Free Sample Report

Several vaccines are being gradually developed to aid in the improvement of the immune system and protect from this infectious disease. Many international institutions such as World Health Organization (WHO) have been engaged in numerous activities to develop and employ vaccines to treat infectious diseases. Cholera is one of the infectious diseases that these institutions have been focusing for to prevent it.

With the support of a strategy named "Ending Cholera: A Global Roadmap to 2030," the WHO’s Global Task Force on Cholera Control (GTFCC) have set various programs to reduce the number of fatalities caused by the disease up to 90% during the targeted period. Oral cholera vaccines (OCV) are made available all around the world with the support of GTFCC to assure immunization, particularly in cholera-prone countries of Africa and Asia.

Kenya executed the Multi-Sectoral Cholera Prevention and Control Plan (MCPCP) from 2011 to 2016 in collaboration with UNICEF to prevent the disease. Furthermore, in December 2012, the United Nations announced a disease-eradication campaign in Haiti and the Dominican Republic. Immunization coverage is steadily increasing over the world.

According to a WHO report conducted in 2014, between 1997 and 2014, approximately 3,175,206 doses of Dukoral and Shanchol were used in vaccination campaigns around the world. A greater number of doses were used in afflicted areas; yet, vaccines are still underused, despite the fact that 1.4 billion people are at risk. The organization further stated that the establishment of a prequalified vaccine factory increased the global supply of OCV to an estimated 6 million in 2016.

According to a WHO article, 1.3 to 4.0 million cases of cholera are reported each year, with 21,000 to 143,000 fatalities worldwide. As per the report, scientists stressed that those people who were lack of access to clean water and basic sanitation are more likely to contract the disease.

Cholera Vaccines Market Trends, Drivers, Restraints, and Opportunities

• Increasing demand for vaccines to be used for disease prevention is expected to fuel the market expansion during the forecast period.
• Rising awareness about cholera preventive care and availability of certain vaccines to cure the disease are anticipated to boost the market growth in the coming years.
• Increasing government focus on immunization programs and wide government policies to enhance the healthcare development are expected to spur market expansion in the coming years.
• Development of novel approaches and practices to new cholera vaccines are projected to push the market growth in the coming years.
• Longer timeline and stringent FDA guidelines for the drug approval of new drug is anticipated to hamper the market growth.

Scope of The Cholera Vaccines Market Report

The report on the global cholera vaccines market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Cholera Vaccines Market Segment Insights

Vaxchora segment is expected to grow at a robust pace

Based on products, the cholera vaccines market is segregated into dukoral, shanchol, vaxchora, and others. The dukoral segment is expected to account for a key share of the market in the coming years owing to established stockpile of this OCV by WHO. It is the only vaccine that protects against diarrhea produced by E. coli that produces heat-labile toxin.

However, the vaxchora segment is anticipated to expand at a rapid pace during the forecast period owing to its benefits like single-dose immunization and fewer side effects. Vaxchora, a single-dose live attenuated OCV, was approved by the US FDA in June 2016 for the use in individuals aged 18 to 64. According to the Center for Infectious Disease Research and Policy, 90 percent of individuals who are vaccinated produce antibodies, which offer immunity against the disease, as per the study of Vaxchora immunogenicity trials conducted in Australia and the US.

Get Free Sample Report

North America is expected to dominate the market

On the basis of regions, the cholera vaccines market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. Asia Pacific is anticipated to dominate the market during the forecast period owing to rising incidence of cholera and growing importance of immunization. The introduction of Shanchol, an OCV, in 2009 increased demand for immunization in the region.

However, the market of North America is expected to exhibit a rapid growth rate in the coming years owing to the introduction of the first and only OCV, Vaxchora, in the US. Furthermore, the number of people from the region travelling to countries where cholera epidemics is occurred often is increasing, which pave more chances to expose to the disease. This leads to raise in the demand for vaccine in the region.

Get Free Sample Report